Cardio Diagnostics Holdings Inc (CDIO)

NASD · Healthcare · Biotechnology · USA

Cardio Diagnostics Holdings Inc is a micro cap company (market value under $300 million) in the Biotechnology industry.

Cardio Diagnostics Holdings develops epigenetics-based clinical blood tests for cardiovascular disease assessment and detection using its AI-driven Multi-Omics Engine. The company offers Epi+Gen CHD for coronary heart disease risk evaluation and PrecisionCHD for disease detection. Its customers include healthcare providers, employers, payors, and health systems.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Cardio Diagnostics Holdings Inc stock.

Our verdict on CDIO

Fairly valued: intrinsic value $1.73 per share, market price $1.71, margin of safety 1.3% (as of 2026-11-17).

Its liquidation floor, current assets minus every liability, values the shares at $1.73; the price of $1.71 is 1% below that value.

ETFs with the most weight in CDIO

More on CDIO

Browse

Peers in Biotechnology

All 600 Biotechnology stocks

Cheaper than CDIO in Biotechnology

21 more in this industry show a wider margin of safety.

Is CDIO undervalued or overvalued?

CDIO is fairly valued (as of the 2026-11-17 close). Its liquidation floor, current assets minus every liability, values the shares at $1.73; the price of $1.71 is 1% below that value.

What is the intrinsic value of CDIO?

$1.73 per share (as of the 2026-11-17 close), against a market price of $1.71. That is a margin of safety of 1.3%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.